阿达木单抗在实现临床和内镜下长期深度缓解方面是有效的:一个病例报告

Gionata Fiorino , Alessandro Repici , Alberto Malesci , Silvio Danese
{"title":"阿达木单抗在实现临床和内镜下长期深度缓解方面是有效的:一个病例报告","authors":"Gionata Fiorino ,&nbsp;Alessandro Repici ,&nbsp;Alberto Malesci ,&nbsp;Silvio Danese","doi":"10.1016/S1594-5804(11)60009-0","DOIUrl":null,"url":null,"abstract":"<div><p>Anti-tumour necrosis factor-alpha has dramatically changed the natural history of Crohn's disease in the last decades. Adalimumab is effective in inducing and maintaining clinical remission as well as in inducing deep mucosal healing, which is a prognostic factor for further progression of the disease. Long-term treatment with adalimumab is considered safe and should be continued for at least 3 years in patients with aggressive long-standing Crohn's disease.</p><p>We report the case of a 61-year-old woman with aggressive and complicated steroid-dependant Crohn's disease in whom clinical and endoscopic long-term deep remission was achieved for up to 3 years, without any need for steroids, hospitalization or surgery.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(11)60009-0","citationCount":"0","resultStr":"{\"title\":\"Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report\",\"authors\":\"Gionata Fiorino ,&nbsp;Alessandro Repici ,&nbsp;Alberto Malesci ,&nbsp;Silvio Danese\",\"doi\":\"10.1016/S1594-5804(11)60009-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Anti-tumour necrosis factor-alpha has dramatically changed the natural history of Crohn's disease in the last decades. Adalimumab is effective in inducing and maintaining clinical remission as well as in inducing deep mucosal healing, which is a prognostic factor for further progression of the disease. Long-term treatment with adalimumab is considered safe and should be continued for at least 3 years in patients with aggressive long-standing Crohn's disease.</p><p>We report the case of a 61-year-old woman with aggressive and complicated steroid-dependant Crohn's disease in whom clinical and endoscopic long-term deep remission was achieved for up to 3 years, without any need for steroids, hospitalization or surgery.</p></div>\",\"PeriodicalId\":100375,\"journal\":{\"name\":\"Digestive and Liver Disease Supplements\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1594-5804(11)60009-0\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digestive and Liver Disease Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1594580411600090\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1594580411600090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在过去的几十年里,抗肿瘤坏死因子- α戏剧性地改变了克罗恩病的自然历史。阿达木单抗在诱导和维持临床缓解以及诱导深层粘膜愈合方面是有效的,这是疾病进一步进展的预后因素。长期使用阿达木单抗治疗被认为是安全的,对于侵袭性长期克罗恩病患者应持续使用至少3年。我们报告一例患有侵袭性和复杂的类固醇依赖性克罗恩病的61岁妇女,其临床和内窥镜长期深度缓解达3年,无需类固醇,住院或手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report

Anti-tumour necrosis factor-alpha has dramatically changed the natural history of Crohn's disease in the last decades. Adalimumab is effective in inducing and maintaining clinical remission as well as in inducing deep mucosal healing, which is a prognostic factor for further progression of the disease. Long-term treatment with adalimumab is considered safe and should be continued for at least 3 years in patients with aggressive long-standing Crohn's disease.

We report the case of a 61-year-old woman with aggressive and complicated steroid-dependant Crohn's disease in whom clinical and endoscopic long-term deep remission was achieved for up to 3 years, without any need for steroids, hospitalization or surgery.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信